Cancer Family
Lung Neoplasm
CI-CAN-00000221Explore in graph →
Non-malignant2,726 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000221Explore in graph →
Clinical trials
11,606 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06419179 | Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)(GUIDANCE) | enrolling by invitation | Phase 2 | 29 | University of CologneOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT06979661 | Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy(PORT) | not yet recruiting | Early Phase 1 | 25 | Rutgers, The State University of New Jersey |
| 1 |
| May 20, 2025 |
| clinicaltrials |
| NCT05441956 | TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 1 | 198 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | May 18, 2025 | clinicaltrials |
| NCT05955391 | TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 2 | 164 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | May 18, 2025 | clinicaltrials |
| NCT06082635 | TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 3 | 321 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | May 18, 2025 | clinicaltrials |
| NCT06659042 | Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer | recruiting | Phase 2 | 32 | Shanghai Chest HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT06978153 | This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Combined With Chemotherapy With or Without Anlotinib in Resectable Limited-Stage Small Cell Lung Cancer | not yet recruiting | Phase 2 | 66 | Tang-Du HospitalOTHER | 0 | May 18, 2025 | clinicaltrials |
| NCT06975384 | The Associations of Sleep Disturbance With Therapy Efficacy and Prognosis of Lung Cancer(Nezha) | recruiting | — | 1,270 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT06976684 | Application of Extended Reality (XR)-Assisted CT-Guided Localization of Pulmonary Nodules in Thoracoscopic Sublobar Resection. | not yet recruiting | N/A | 20 | National Taiwan University HospitalOTHER | 0 | May 16, 2025 | clinicaltrials |
| NCT06968221 | Bovine Reinforcement in Stomach, Colorectal and Lung Operation | recruiting | Phase 3 | 172 | Shanghai Cingularbio Co. LtdINDUSTRY | 1 | May 15, 2025 | clinicaltrials |
| NCT06972576 | Clinical Study of Combined EphA2-targeted CAR-DC and CAR-T Cell Therapy for Non-small Cell Lung Cancer | recruiting | Phase 1 | 18 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06165419 | Definitive Radiation for High-Risk Spine Metastases | recruiting | Phase 2 | 26 | Stony Brook UniversityOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06969781 | MWA With or Without Furmonertinib for Early-Stage Non-Small Cell Lung Cancer | not yet recruiting | N/A | 120 | Shanghai Chest HospitalOTHER | 0 | May 14, 2025 | clinicaltrials |
| NCT06970795 | A Study of SYS6040 for Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 180 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | May 14, 2025 | clinicaltrials |
| NCT06971406 | High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis(FLAME-1) | not yet recruiting | Phase 2 | 100 | Qiming WangOTHER_GOV | 0 | May 14, 2025 | clinicaltrials |
| NCT06332274 | tislelizUMaB in canceR Patients With molEcuLar residuaL Disease(UMBRELLA) | recruiting | Phase 3 | 717 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06967532 | Efficacy of Torque Teno Virus as a Biomarker for Predicting Treatment Response of Immune Checkpoint Inhibitor Therapy and Postoperative Outcome in NSCLC Patients(TTV in NSCLC) | recruiting | — | 90 | Medical University of ViennaOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06966583 | NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLC(NMN) | not yet recruiting | Phase 1 | 20 | Sichuan UniversityOTHER | 1 | May 12, 2025 | clinicaltrials |
| NCT06963307 | Novel Epigenetic Mapping in Cell-Free DNA for the Detection of Lung Cancer(LumenDx) | recruiting | — | 300 | JaxBio LtdINDUSTRY | 1 | May 9, 2025 | clinicaltrials |
| NCT06963502 | A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 762 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 9, 2025 | clinicaltrials |
| NCT06963515 | Cutting-edge IMAGING Technologies to Improve the SAFEty and the Sustainability of LUNG Cancer Screening and the Accuracy of Non-invasive Lung Nodules Characterization | not yet recruiting | — | 250 | IRCCS San RaffaeleOTHER | 0 | May 9, 2025 | clinicaltrials |
| NCT06964503 | Impact of Psychological Stress on Treatment Response and Prognosis in Lung Cancer Patients | not yet recruiting | — | 600 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | May 9, 2025 | clinicaltrials |
| NCT05631249 | Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C(CODEBREAK-IGR) | recruiting | Phase 2 | 40 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT06962189 | The Efficacy and Safety of Sintilimab Plus Chemotherapy in Surgical Conversion for Patients With Unresectable Stage IIIB-IIIC NSCLC: A Prospective, Single-Arm, Phase II Study | not yet recruiting | Phase 2 | 39 | Zhejiang UniversityOTHER | 0 | May 8, 2025 | clinicaltrials |
| NCT06962449 | Real-World Assessment of Therapeutic Strategies and Survival Outcomes Following First-Line Tislelizumab Therapy in Advanced Non-Small Cell Lung Cancer(REALM-Post) | enrolling by invitation | — | 500 | Shanghai Chest HospitalOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT06962670 | Predicting Cancer Risk With Digital and Molecular Markers(PräDigt) | recruiting | N/A | 1,250 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT06498986 | A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | recruiting | Phase 2 | 40 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 7, 2025 | clinicaltrials |
| NCT06961201 | Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase | not yet recruiting | Phase 3 | 94 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 7, 2025 | clinicaltrials |
| NCT02983578 | Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer | active not recruiting | Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT05179824 | Tempus Priority Study: A Pan-tumor Observational Study | active not recruiting | — | 1,000 | Tempus AIINDUSTRY | 1 | May 6, 2025 | clinicaltrials |
| NCT06401824 | Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases | recruiting | Phase 2 | 25 | Maastricht University Medical CenterOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT06955325 | Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations(UPLIFT) | not yet recruiting | Phase 3 | 270 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | May 6, 2025 | clinicaltrials |
| NCT06959173 | Organoid-guided Personalized Treatment of Pleural Effusion | recruiting | — | 20 | Henan Cancer HospitalOTHER_GOV | 1 | May 6, 2025 | clinicaltrials |
| NCT05621837 | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy(Serpentine) | recruiting | — | 1,000 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT05384873 | Immunonutrition for Improving the Efficacy of Immunotherapy in Patients With Metastatic Non-small Cell Lung Cancer(MURAL) | recruiting | N/A | 180 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT06953765 | A Prospective Study: the Impact of Sleep Disturbances on Immunotherapy in Patients With Lung Cancer | not yet recruiting | — | 350 | Shanghai Zhongshan HospitalOTHER | 0 | May 1, 2025 | clinicaltrials |
| NCT05352035 | Multiomics Tumor Evolution Model of NSCLC | recruiting | — | 300 | Peking University People's HospitalOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT05835570 | Integrin αvβ6-targeted PET in Malignant Tumors | recruiting | — | 200 | Zhongnan HospitalOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT05994131 | IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC | recruiting | Phase 1 / Phase 2 | 110 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 1 | Apr 30, 2025 | clinicaltrials |
| NCT06951841 | Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction | not yet recruiting | Phase 4 | 31 | China Medical University, ChinaOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT06948539 | To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors | not yet recruiting | Phase 1 | 66 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06718972 | A Real-world Study on the Treatment of Non-small Cell Lung Cancer With Leptomeningeal Metastasis in China(CLM-tree datab) | recruiting | — | 1,000 | Guangzhou Medical UniversityOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06946836 | Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical Study(Neoadjuvant) | not yet recruiting | Phase 2 | 80 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Apr 27, 2025 | clinicaltrials |
| NCT05736731 | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression(EVEREST-1) | active not recruiting | Phase 1 / Phase 2 | 160 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06056128 | Confirmation of Accuracy of the Tool-in-lesion Technology (TiLT) of the Galaxy System With Integrated TOMO Technology(TiLT) | active not recruiting | N/A | 25 | Noah MedicalINDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06914050 | Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Apr 25, 2025 | clinicaltrials |
| NCT06942845 | Exploration of Risk Factors for Postoperative Cerebral Infarction in Lung Cancer Patients: a Retrospective Single-centre Study | active not recruiting | — | 300 | Xinghua ChengOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT06046495 | A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer | recruiting | Phase 1 | 81 | Avistone Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 23, 2025 | clinicaltrials |
Data updated 24 days agoSource updated May 20, 2025source: clinicaltrials